CN116056713B - 肠道微生物群生物活性pde4抑制剂前体 - Google Patents

肠道微生物群生物活性pde4抑制剂前体

Info

Publication number
CN116056713B
CN116056713B CN202180058681.5A CN202180058681A CN116056713B CN 116056713 B CN116056713 B CN 116056713B CN 202180058681 A CN202180058681 A CN 202180058681A CN 116056713 B CN116056713 B CN 116056713B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
pyridin
acceptable salt
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180058681.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN116056713A (zh
Inventor
B·科特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiante Pharmaceutical Co
Original Assignee
Jiante Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiante Pharmaceutical Co filed Critical Jiante Pharmaceutical Co
Publication of CN116056713A publication Critical patent/CN116056713A/zh
Application granted granted Critical
Publication of CN116056713B publication Critical patent/CN116056713B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180058681.5A 2020-05-28 2021-05-28 肠道微生物群生物活性pde4抑制剂前体 Active CN116056713B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063031023P 2020-05-28 2020-05-28
US63/031,023 2020-05-28
PCT/CA2021/050725 WO2021237364A1 (en) 2020-05-28 2021-05-28 Gut microbiota bioactivated pde4 inhibitor precursors

Publications (2)

Publication Number Publication Date
CN116056713A CN116056713A (zh) 2023-05-02
CN116056713B true CN116056713B (zh) 2025-09-09

Family

ID=78745382

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180058681.5A Active CN116056713B (zh) 2020-05-28 2021-05-28 肠道微生物群生物活性pde4抑制剂前体

Country Status (9)

Country Link
US (1) US20230250123A1 (https=)
EP (1) EP4157853B1 (https=)
JP (1) JP7762168B2 (https=)
KR (1) KR20230029682A (https=)
CN (1) CN116056713B (https=)
AU (1) AU2021280418A1 (https=)
ES (1) ES2989065T3 (https=)
MX (1) MX2022014416A (https=)
WO (1) WO2021237364A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200993B1 (en) * 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
CN101495454A (zh) * 2006-05-31 2009-07-29 查珀尔希尔北卡罗来纳大学 新型pde4抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY123585A (en) * 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
AU2003281219A1 (en) * 2002-07-02 2004-01-23 Bernard Cote Di-aryl-substituted-ethane pyridone pde4 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200993B1 (en) * 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
CN101495454A (zh) * 2006-05-31 2009-07-29 查珀尔希尔北卡罗来纳大学 新型pde4抑制剂

Also Published As

Publication number Publication date
MX2022014416A (es) 2023-02-22
KR20230029682A (ko) 2023-03-03
JP7762168B2 (ja) 2025-10-29
JP2023528397A (ja) 2023-07-04
EP4157853B1 (en) 2024-07-31
US20230250123A1 (en) 2023-08-10
CN116056713A (zh) 2023-05-02
ES2989065T3 (es) 2024-11-25
WO2021237364A1 (en) 2021-12-02
AU2021280418A1 (en) 2023-02-02
CA3174137A1 (en) 2021-12-02
EP4157853A1 (en) 2023-04-05
EP4157853A4 (en) 2023-12-13
EP4157853C0 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
JP5969471B2 (ja) パラミクソウイルス科ウイルス感染症を治療するための方法及び化合物
RU2667060C2 (ru) Производные маннозы для лечения бактериальных инфекций
TWI499414B (zh) 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
CN111801339B (zh) 5-氟尿嘧啶化合物
US9890176B2 (en) Mannose derivatives for treating bacterial infections
EP3174879B1 (en) Substituted oxetanes and their use as inhibitors of cathepsin c
US20130261077A1 (en) Mannose derivatives for treating bacterial infections
US20140107049A1 (en) Mannose derivatives for treating bacterial infections
EP2604619A2 (en) Mannose derivatives as antagonists of bacterial adhesion
AU2009231258A1 (en) Compounds for treating muscular dystrophy
KR102682408B1 (ko) 신규한 벤조티아졸 유도체, 이의 제조방법 및 이의 간질환 예방 또는 치료 용도
CN116056713B (zh) 肠道微生物群生物活性pde4抑制剂前体
CA3174137C (en) Gut microbiota bioactivated pde4 inhibitor precursors
WO2006059163A1 (en) Treatment of diabetes with glycogen phosphorylase inhibitors
HK40093996A (zh) 肠道微生物群生物活性pde4抑制剂前体
WO2012055169A1 (zh) C-芳基葡糖苷衍生物及其制备方法和应用
CA2988680A1 (en) Mannose derivatives for treating bacterial infections
CN121002023A (zh) 趋化因子受体调节剂制备方法和用途
WO2018172129A1 (de) Sialinsäurederivate mit c-c dreifachbindung und deren herstellung
TW201623321A (zh) 雙環衍生物及包含其之藥學組成物
CN113943330A (zh) 一类含糖结构化合物、其制备方法、药物组合物和用途
JP2012096997A (ja) ヌクレオシド系抗生物質
JP2014516038A (ja) Ｓｇｌｔ−２の阻害物質として有用な化合物の調製プロセス
NZ711932B2 (en) Mannose derivatives for treating bacterial infections
HK1163109B (en) Bicyclic derivatives of morphine-6-glucuronide, process for their preparation and their application in therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40093996

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant